Innovent Biologics (HKEX: 01801) has formed a strategic partnership with ASK Pharm (SZ: 002755) to commercialize limertinib, ...
Less frequent dosing could provide Eli Lilly’s Ebglyss room to rival Sanofi and Regeneron’s blockbuster Dupixent.
Co-development agreements involve both companies working together to develop a specific product or technology.
With its recent US Food and Drug Administration (FDA) approval, Eli Lilly’s Ebglyss (lebrikizumab) adds a new competitor to ...
The Nifty Pharma index closed on a positive note on Tuesday. Shares of Glenmark Pharmaceuticals Ltd.(up 3.55 per cent), Ipca ...
The Indian pharmaceutical sector faces mixed growth with a 12% YoY and 5% QoQ rise while IPM growth is projected at 8%.
Among the large drugmakers, Eli Lilly, AstraZeneca, Pfizer, Sanofi and Bayer are worth retaining in one’s portfolio.
The Indian pharmaceutical sector is anticipating a mixed quarter with overall slow growth, but key players like Dr. Reddy's ...
Nifty moved in a tight range of 82 points, and ended slightly below the psychologically crucial level of 15,700. NEW DELHI: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback